Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature

General Pharmacology

Volumn 29, Issue 2, 1997, Pages 229-232

  Yatsu, Takeyuki ^a   Uchida, Wataru ^a   Inagaki, Osamu ^a   Tanaka, Akihiro ^a   Takenaka, Toichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Agonist; Dopamine DA1; Peripheral dopamine receptors; Renal blood flow; Renal vasculature; YM435

Indexed keywords

4 (3,4 DIHYDROXYPHENYL) 1,2,3,4 TETRAHYDRO 7,8 DIHYDROXYISOQUINOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EMONAPRIDE; FENOLDOPAM; PHENOXYBENZAMINE; PROPRANOLOL; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR STIMULATING AGENT; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; INTRAARTERIAL DRUG ADMINISTRATION; KIDNEY ARTERY; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; VASODILATATION; ANIMAL; BLOOD FLOW; COMPARATIVE STUDY; DRUG EFFECT; KIDNEY; VASCULARIZATION;

ANIMALS; DOGS; DOPAMINE; DOPAMINE AGONISTS; FEMALE; FENOLDOPAM; ISOQUINOLINES; KIDNEY; MALE; REGIONAL BLOOD FLOW; TETRAHYDROISOQUINOLINES; VASODILATOR AGENTS;

EID: 0030610539     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00402-8     Document Type: Article

References (25)

1. 1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. Chem. Pharm. Bull. 39, 2910-2914.
2. Anan H., Tanaka A., Tsuzuki R., Yokota M., Yatsu T. and Fujikura T. (1996) 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship. Chem. Pharm. Bull. 44, 1865-1870.
3. 2 classification. Trends Pharmac. Sci. 11, 231-236.
4. Felder R. A., Felder C. C., Eisner G. M. and Jose P. A. (1989) The dopamine receptor in adult and maturing kidney. Am. J. Physiol. 257, F315-F327.
5. Goldberg L. I., Sonneville P. F. and McNay J. L. (1968) An investigation of the structural requirements for dopamine-like renal vasodilation: phenethylamines and apomorphine. J. Pharmac. Exp. Ther. 163, 188-197.
6. Goldberg L. I. (1972) Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmac. Rev. 24, 1-29.
7. Goldberg L. I., Hsieh Y. Y. and Resnekov L. (1977) Newer catecholamines for treatment of heart failure and shock: an update of dopamine and a first look at dobutamine. Prog. Cardiovasc. Dis. 19, 327-340.
8. Goldberg L. I. and Kohli J. D. (1983) Peripheral dopamine receptors: a classification based on potency series and specific antagonism. Trends Pharmac. Sci. 4, 64-66.
9. Goldberg L. I. and Rajfer S. I. (1985) Dopamine receptors: applications in clinical cardiology. Circulation 72, 245-248.
10. Hahn R. A., Wardell J. R., Sarau H. M. and Ridley P. T. (1982) Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J. Pharmac. Exp. Ther. 223, 305-313.
11. Hilditch A., Drew G. M. and Naylor R. J. (1984) SCH 23390 is a very potent and selective antagonist at vascular dopamine receptors. Eur. J. Pharmac. 97, 333-334.
12. Hollenberg N.K. (1988) Control of renal perfusion and function in congestive heart failure. Am. J. Cardiol. 62, 72E-75E.
13. Hollenberg N. K. and Adams D. F. (1976) The renal circulation in hypertensive disease. Am. J. Med. 60, 773-784.
14. 2 dopamine receptors in the dog renal vasculature. Eur. J. Pharmac. 197, 125-130.
15. Kebabian J. W. and Calne D. B. (1979) Multiple receptors for dopamine. Nature 277, 93-96.
16. 1 receptor antagonist. J. Pharm. Pharmac. 38, 401-402.
17. 1 receptor agonist. Eur. J. Pharmac. 235, 31-35.
18. Lee M. R. (1982) Dopamine and the kidney. Clin. Sci. 62, 439-448.
19. MacDonald R. H., Goldberg L. I., McNay J. L. and Tuttle E. P. (1964) Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J. Clin. Invest. 43, 1116-1124.
20. Middlekauff H. R., Nitzsche E. U., Hamilton M. A., Schelbert H. R., Fonarow G. C., Moriguchi J. D., Hage A., Saleh S. and Gibbs G. G. (1995) Evidence for preserved cardiopulmonary baroreflex control of renal cortical blood flow in humans with advanced heart failure. A positron emission tomography study. Circulation 92, 395-401.
21. Ruilope L. M., Lahera V., Rodicio J. L. and Romero J. C. (1994) Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 23, 3-9.
22. Sibley D. R. and Monsma F. J. (1992) Molecular biology of dopamine receptors. Trends Pharmac. Sci. 13, 61-69.
23. Stein J. H., Lifschitz M. D. and Barnes L. D. (1978) Current concepts on the pathophysiology of acute renal failure. Am. J. Physiol. 234, F171-F181.
24. 1) agonist, YM435. J. Pharmac. Exp. Ther. 264, 1154-1159.
25. Yeh B. K., McNay J. L. and Goldberg L. I. (1969) Attenuation of dopamine renal and mesenteric vasodilatation by haloperidol: evidence for a specific dopamine receptor. J. Pharmac. Exp. Ther. 168, 303-309.